Valeant announced it will report third quarter earnings on November 8 at 8 a.m. Needless to say, the analyst consensus estimates vary widely, ranging from $1.65 per share to $2.95 per share. Expectations that the company will report a drop in revenue by 10 percent should not concern investors looking for the company to turn its business around.
Ophthalmology, gastroenterology, and dermatology are two of Valeant’s strongest units. Xifaxan sales may improve; if the company continues raising advertising spend to raise awareness for the brand. With short float a modestly high 8.29 percent, bears are betting a miss in any one of the three areas will send shares lower. Already, VRX stock was met with resistance at $30 (my price target was $29), settling recently at $21.96.
$21 is a critical juncture for VRX stock. Look for bears trying to push the stock lower, creating an entry point. Valeant must report and end to revenue declines, avoid selling assets at this time and re-affirming the FY 2016 forecast. If it does this, VRX will make another run towards $30 and above.